Anthem Biosciences Ltd (ANTHEM) — shareholding pattern, promoter holding, financials and share price
About Anthem Biosciences Ltd (ANTHEM)
Anthem Biosciences Ltd operates in the Biotechnology industry, within the Healthcare sector. It trades on the NSE as ANTHEM and on the BSE under scrip code 544449. Its ISIN is INE0CZ201020.
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients. [1]
Anthem Biosciences Limited specializes in manufacturing specialty organic molecules and biologically active peptides, catering primarily to the drug and specialty chemicals industries.
The company reported a decline in quarterly revenue, with Q3FY26 showing a 15% year-over-year decrease compared to Q3FY25, while maintaining robust EBITDA margins around 41.8%.
Listed peers in Biotechnology: Ipca Laboratories Ltd, Ajanta Pharma Ltd, Glaxosmithkline Pharmaceuticals Ltd, Gland Pharma Ltd, J B Chemicals & Pharmaceuticals Ltd, Emcure Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹755.45 a share on 10 Jul 2026, Anthem Biosciences Ltd (ANTHEM) was valued at a price-to-earnings ratio of 71.92x against an industry P/E of 36.41x and a price-to-book of 13.99x on a book value of ₹54 per share as of Mar 2026. Solomo computes return on equity of 19.45% and return on capital employed of 26.84% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 71.92x
- Industry P/E
- 36.41x
- P/B
- 13.99x
- EPS (TTM)
- ₹10.5
- Book value / share
- ₹54
- ROE
- 19.45%
- ROCE
- 26.84%
- ROA
- 17.26%
- Debt / equity
- 0.02x
- Dividend yield
- 0.26%
- EBITDA margin
- 45.44%
- 52-week range
- ₹579.45 – ₹873.25
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Anthem Biosciences Ltd (ANTHEM) reported revenue of ₹2,124 crore, net profit of ₹592 crore and earnings per share of ₹10.54. That compares with revenue of ₹1,845 crore and net profit of ₹451 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹611 crore and net profit ₹190 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 |
| Net profit (₹ cr) | 406 | 385 | 367 | 451 | 592 |
| EPS (₹) | 462.09 | 6.75 | 6.57 | 8.07 | 10.54 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 13.62% | 25.50% | 15.17% |
| Profit growth | 19.84% | 20.25% | 31.14% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.42% of Anthem Biosciences Ltd (ANTHEM) (down 3.26 pp QoQ), foreign institutional investors (FII) hold 2.58% and domestic institutional investors (DII) hold 13.48%. Market capitalisation was ₹42,561 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Jun 2026: PORTSMOUTH TECHNOLOGIES LLC 2.73%, HDFC TRUSTEE COMPANY LIMITED-HDFC FLEXI CAP FUND 2.44%, MALAY JIBAN BARUA 2.26%, SATISH S SHARMA 2.26%, RUPESH NARHARRAO KINEKAR 2.21%, SBI MNC FUND 1.76%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.42% | - | 2.58% | 13.48% | 28.58% |
| Mar 2026 | 74.68% | - | 1.28% | 11.55% | 25.32% |
| Dec 2025 | 74.69% | - | 1.36% | 7.6% | 25.31% |
| Sep 2025 | 74.69% | - | 1.67% | 7.22% | 25.31% |